Year: 2014-15
Company: Atom Inc.
Liaison(s): Andy Coy Dan Bradbury Kris Smolinski
Atom, Inc. is engaged in the production of carbon nanotubes for a variety of applications within the commercial and military markets. They have established methods to produce carbon nanotubes (CNTs) at high yields and purity. Atom researches, develops, and commercializes carbon nanotube (CNT) based organic light-emitting diode (OLED) and active-matrix OLED (AMOLED) technologies for use in flat-panel displays, solid-state lighting, and other electronic products. Atom’s new technology is a lowcost, scalable solution that competes favorably against current semiconducting electronics both in terms of production costs and available technology. Atom, Inc. is interested in understanding the market opportunity for biometric sensors that can measure various biomarkers including creatine, glucose, etc., and biometrics like body temperature, blood pressure, and heart rate. The company would like the TMP team to investigate the global market for CNT based sensors and to recommend appropriate opportunities to pursue. Atom, Inc.’s ultimate goal is to improve the health outcomes of patients by using their carbon nanotube biosensor technology to increase sensitivity and improve the specificity of important biological measurements. The Atom, Inc. TMP Team evaluated various disease states and their respective markets to assess unmet clinical need within the diagnostic arena. To achieve this objective, the team focused on the provider pathway, the market size, the competitive landscape, and the health outcomes of each opportunity. In addition, our TMP group utilized a combination of primary and secondary research to provide a final recommendation to Atom, Inc. With support and input from the Atom Nanoelectronics executive board, our TMP team created a commercialization strategy which allows Atom, Inc. to enter the medical diagnostic marketplace.